After more than 25 years working with biotech innovators, I’ve learned that the real value of a patent family lies in the inventive scope where your science, legal strategy, and innovation truly meet . That intersection is what I call the patent sweet spot . So, what exactly is the sweet spot? It’s the range of claim scope that matches the working examples in your application — broad enough to protect what matters commercially, but grounded enough in data to avoid overreach

Innovation, collaboration, and thoughtful IP strategy, that’s what built Invitrogen’s success. And it’s still what drives the best...

The Lip Service Problem In 25+ years of working with biotech leadership teams, I’ve heard countless executives assure investors,...

Why Your Biotech Patent Keeps Getting Rejected, and What to Do About It. If your biotech patent application keeps getting rejected, it’s...

“Bio/pharma funding deal data in H1 2025 reveals a troubling downward shift starting in February.” Investment in bio/pharma was down in...

(Check out the short version of this post, if you don't want all the details in this patent professional version.) Introduction: It can...

Biotech products and processes evolve over time. This can cause a misalignment between your issued/pending patent claims, and your...

INTRODUCTION Executives usually ask these quantitative but high-level questions: How much money did we spend on patent work this year?...

As a biotech company, much of your value is in (pre-revenue) and/or protected by (post-revenue) your intellectual property. As you...

Working examples are an important part of a biotech patent application, especially because this is considered an unpredictable art in...

SUMMARY Costs for prosecuting patents at the USPTO are set to increase on 1/19/25 Across-the-board 7.5% increase in fees Some targeted...

Like many technology areas, the vast majority of, if not all, biotech/biopharma inventions build on prior art teachings. Thus, a major...

The USPTO has provided 49 examples* to help understand the application of Section 101 (35 U.S.C. 101), subject matter eligibility, in...

Common misconceptions about patent rights: In my decades of counseling life sciences companies, I have found that many inventors and...

When should we assure we have FTO for our private biotech company? Summary: FTO for a private biotech company is typically a multi-stage...

101 rejections at the USPTO plummeted in computational biology in 2023!      We analyzed office actions since 2008 related to...

INTRODUCTORY COMMENTS RE: BIOTECH/PHARMA EXTENDED PATENT FAMILIES In complex art areas like biotech/biopharma, patent strategy is about...

The $AMRN/Vascepa story... A sad 🥲 but insightful🤔 story about the value of U.S. biopharma patents From ~$23/share to ~$1/share in ~5...

If you are interested in learning more about prior patent term extension filings, the USPTO and FDA provide some helpful links, which are...

March 26, 2023 The U.S. Supreme Court will hear oral arguments tomorrow in Amgen v. Sanofi, an important biotech enablement case. The...